Floatz logo

Therapeutic Asset Ratings

5,098 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Belzutifan
Von Hippel-Lindau Disease
Merck Sharp & Dohme LLCP3B (61)
Bgb-43395
Hormone Receptor-Positive Breast Cancer
BeOne MedicinesP3B (61)
Binimetinib
Melanoma
The Christie NHS Foundation TrustP3B (61)
bnt323
Breast Cancer
BioNTech SEP3B (61)
Brentuximab Vedotin
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Assistance Publique - Hôpitaux de ParisP3B (61)
Brentuximab Vedotin
Primary Cutaneous Anaplastic Large Cell Lymphoma
John ReneauP3B (61)
Cabozantinib
Differentiated Thyroid Carcinoma
ExelixisP3B (61)
Cabozantinib
Cancer
ExelixisP3B (61)
Cetuximab
Rectum Adenocarcinoma
Sixth Affiliated Hospital, Sun Yat-sen UniversityP3B (61)
Cetuximab
Cancer
National Cancer Institute (NCI)P3B (61)
Citicoline
Ischemic Stroke
Kafrelsheikh UniversityP3B (61)
Colchicinum
Atherosclerosis
University College DublinP3B (61)
Concizumab
Hemophilia B
Novo Nordisk A/SP3B (61)
Cyclosporin A
Childhood Acute Myeloid Leukemia
Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyP3B (61)
Cyclosporin A
Chronic Myeloid Leukemia
Fred Hutchinson Cancer CenterP3B (61)
Cyclosporin A
Myelodysplastic Syndrome
City of Hope Medical CenterP3B (61)
Dabrafenib
Cancer
Cancer Research UKP3B (61)
Dabrafenib
Cutaneous Melanoma
Immuneering CorporationP3B (61)
Dasatinib
Acute Lymphoblastic Leukemia
Nanfang Hospital, Southern Medical UniversityP3B (61)
Datopotamab Deruxtecan
Non-Small Cell Lung Carcinoma
Memorial Sloan Kettering Cancer CenterP3B (61)
Dexasone
Amyloidosis
Ascentage Pharma Group Inc.P3B (61)
Dexasone
B-Cell Acute Lymphoblastic Leukemia
SWOG Cancer Research NetworkP3B (61)
Dexasone
Cancer
Merck Sharp & Dohme LLCP3B (61)
Dexasone
Follicular Lymphoma
GenmabP3B (61)
Droxidopa
Pure Autonomic Failure
Vanderbilt University Medical CenterP3B (61)
Showing 2526 to 2550 of 5,098 assets
PreviousPage 102 of 204Next